ArticleFrontiers in medicine2025
Analysis of gender- and age-stratified asthma burden: forecasting prevalence trends in 2030.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Effectiveness and Safety of Budesonide/Formoterol in Asthma: A Systematic Review.Healthcare (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Asthma poses a global health challenge, requiring an understanding of its burden to guide policy. Using GBD 2021 data, this study aims to assess the burden of asthma worldwide. Methods: We extracted data on asthma prevalence, incidence, years lived with disability (YLDs), and disability-adjusted life-years (DALYs) from GBD for the period 1990-2021. Age-standardized rates (ASR) and estimated annual percentage changes (EAPC) were calculated to understand trends. We analyzed variations in asthma burden across gender and age groups, and explored the correlation between socio-demographic index (SDI) and asthma burden. Furthermore, we examined the main risk factors contributing to asthma. Lastly, we predicted the future asthma burden over the next 8 years. Results: High population countries such as India and China reported higher numbers of prevalence, incidence, and YLDs. From 1990 to 2021, the ASR of prevalence, incidence, and YLDs for asthma showed an overall downward trend. Children under 14 years of age demonstrated notably higher incidence rates, with the highest concentrations observed among those below 5 years, whereas the elderly population (>90 years) exhibited the peak prevalence and disability-adjusted life years (DALYs) burden. Gender differences were observed, with males having a higher burden before age 15-19, and females afterward. In China, smoking emerged as a significant risk factor for men, while the risk associated with high body mass index (BMI) has increased notably in recent years. Both incidence and prevalence in China are projected to decrease in the future. Conclusion: This study finds 15-19 years is a key turning point for gender differences in asthma burden, pinpointing smoking, high BMI, and NO₂ as risk factors. From 2022-2030, asthma prevalence/incidence is set to decline overall but rise in 15-19-year-olds, highlighting adolescence as a new prevention focus and a call for better health education in China.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.